Anand Devaraj
Seminars
Thursday 1st October 2026
Beyond FVC: Delivering Advanced Imaging Endpoints for Next Generation IPF/ILD Trials
9:00 am
- Explore how Brainomix’ validated quantitative HRCT biomarkers can deliver patient stratification, baseline risk profiling, and objective evaluation of multi-parameter disease progression and treatment response
- Discuss the operational pathway to implementing imaging endpoints robustly and at scale, including standardized acquisition, image quality control, central review and automated AI-powered quantitative CT processing through the Voiant Hub platform
- Review the latest clinical evidence and relevant trials such as the Phase III DROP FPF study which has included advanced AI imaging biomarkers as a co-primary endpoint to complement FVC and conventional trial endpoints
